問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Radiation Therapy

Division of Hematology & Oncology

Division of General Internal Medicine

Division of Urology

Cheng Hsin General Hospital

Division of Hematology & Oncology

更新時間：2023-09-19

劉俊煌Liu, Jin-Hwang
  • Principal Investigator
  • Clinical Trial Experience (year) -23 years -3 個月

Recruiting Trial

1Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

劉俊煌

List

49Cases

2025-03-01 - 2029-03-01

Phase III

Active
A randomized, double-blind, placebo-controlled, multicenter phase 3 clinical trial evaluating the efficacy and safety of Ropeginterferon alfa-2b (P1101) in adult patients with pre-fibrotic/early primary myelofibrosis or marked primary myelofibrosis classified as low- or intermediate-risk 1 according to DIPSS Plus (HOPE-PMF): core trial and its extension trial.

  • Condition/Disease

    Clinically relevant complete hematologic response (CrCHR) at week 80, and symptom assessment indicators at week 80. CrCHR was defined as: 1. Platelet count ≤ 400 x 10^9/L, and 2. White blood cell (WBC) ≤ 10 x 10^9/L, and 3. Peripheral blood: Heme (Hgb) ≥ 10.0 g/dL, and 4. No major thrombotic events, and 5. No progression to secondary acute myeloid leukemia (AML). Symptom assessment indicators were defined as: 6. No worsening of clinical symptoms according to the MFSAF Total Symptom Score (TSS) version 4.0; no worsening of clinical symptoms was defined as: - If the baseline TSS score ≤ 10, then the TSS score remained ≤ 10; or - If the baseline TSS score > 10, then the TSS score did not increase by > 50%.

  • Test Drug

    Ropeginterferon alfa-2b (P1101)

Participate Sites
14Sites

Recruiting14Sites

2004-02-01 - 2006-10-01

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2010-06-01 - 2015-05-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2005-11-01 - 2008-01-01

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2008-06-01 - 2010-03-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

2010-12-01 - 2018-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2005-08-01 - 2008-06-01

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2017-11-01 - 2022-12-31

Phase I/II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2016-09-01 - 2020-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

黃逸修
Taipei Veterans General Hospital

Division of Urology

2014-01-01 - 2021-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB